Search research articles
Contact Us
Filters
Showing results (21-30 of 39) with videos related to
Page
of 4
Sort By:
Cell Death and Differentiation
|
February 9, 2023
MNT suppresses T cell apoptosis via BIM and is critical for T lymphomagenesis
Hai Vu Nguyen, Cassandra J Vandenberg, Mikara R Robati, et al.
Cell Death and Differentiation
|
August 12, 2017
Mnt modulates Myc-driven lymphomagenesis
Kirsteen J Campbell, Cassandra J Vandenberg, Natasha S Anstee, et al.
Cell Death & Disease
|
September 2, 2016
Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice
Rebecca A Bilardi, Natasha S Anstee, Stefan P Glaser, et al.
The FEBS Journal
|
March 3, 2018
Differential effects of Vav-promoter-driven overexpression of BCLX and BFL1 on lymphocyte survival and B cell lymphomagenesis
Selma Tuzlak, Manuel D Haschka, Anna-Maria Mokina, et al.
Cell Death and Differentiation
|
November 5, 2016
Overexpression of Mcl-1 exacerbates lymphocyte accumulation and autoimmune kidney disease in lpr mice
Natasha S Anstee, Cassandra J Vandenberg, Kirsteen J Campbell, et al.
Cell Death and Differentiation
|
November 25, 2018
Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice
Natasha S Anstee, Rebecca A Bilardi, Ashley P Ng, et al.
Cell Death and Differentiation
|
January 18, 2018
Anti-apoptotic A1 is not essential for lymphoma development in Eµ-Myc mice but helps sustain transplanted Eµ-Myc tumour cells
Mark Mensink, Natasha S Anstee, Mikara Robati, et al.
Blood
|
July 16, 2010
Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance
Kirsteen J Campbell, Mary L Bath, Marian L Turner, et al.
Blood Neoplasia
|
October 27, 2025
MNT: a new target for AML
Karla C Fischer, Veronique Litalien, Sarah T Diepstraten, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 14, 2008
In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas
Kylie D Mason, Cassandra J Vandenberg, Clare L Scott, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 39) with videos related to
Sort By:
Page
of 4
Cell Death and Differentiation
|
February 9, 2023
MNT suppresses T cell apoptosis via BIM and is critical for T lymphomagenesis
Hai Vu Nguyen, Cassandra J Vandenberg, Mikara R Robati, et al.
Cell Death and Differentiation
|
August 12, 2017
Mnt modulates Myc-driven lymphomagenesis
Kirsteen J Campbell, Cassandra J Vandenberg, Natasha S Anstee, et al.
Cell Death & Disease
|
September 2, 2016
Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice
Rebecca A Bilardi, Natasha S Anstee, Stefan P Glaser, et al.
The FEBS Journal
|
March 3, 2018
Differential effects of Vav-promoter-driven overexpression of BCLX and BFL1 on lymphocyte survival and B cell lymphomagenesis
Selma Tuzlak, Manuel D Haschka, Anna-Maria Mokina, et al.
Cell Death and Differentiation
|
November 5, 2016
Overexpression of Mcl-1 exacerbates lymphocyte accumulation and autoimmune kidney disease in lpr mice
Natasha S Anstee, Cassandra J Vandenberg, Kirsteen J Campbell, et al.
Cell Death and Differentiation
|
November 25, 2018
Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice
Natasha S Anstee, Rebecca A Bilardi, Ashley P Ng, et al.
Cell Death and Differentiation
|
January 18, 2018
Anti-apoptotic A1 is not essential for lymphoma development in Eµ-Myc mice but helps sustain transplanted Eµ-Myc tumour cells
Mark Mensink, Natasha S Anstee, Mikara Robati, et al.
Blood
|
July 16, 2010
Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance
Kirsteen J Campbell, Mary L Bath, Marian L Turner, et al.
Blood Neoplasia
|
October 27, 2025
MNT: a new target for AML
Karla C Fischer, Veronique Litalien, Sarah T Diepstraten, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 14, 2008
In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas
Kylie D Mason, Cassandra J Vandenberg, Clare L Scott, et al.
Page
of 4